Mayo Clinic Study Finds Chromosomal Rearrangements Help Distinguish Between Independent Primary Tumors and Metastasis
A Mayo Clinic study has found a diagnostic test based on chromosomal rearrangements can trace the lineage of lung cancer to determine whether two separate lung cancers in the same patient are independent tumors or a tumor that has spread to another region of the lung. For patients with multiple tumors, that distinction could mean the difference between early stage cancer that may be cured by surgery and incurable late-stage disease.
GenomeDx Biosciences today announced that the company has expanded its research agreement with Mayo Clinic to initiate a validation study to expand the use of the Decipher® Prostate Cancer Classifier, a genomic test capable of predicting metastatic prostate cancer, for use in prostate biopsy specimens.
Utilizing the "frozen sections" technique, Mayo Clinic surgical and laboratory teams work together to provide patients immediate treatment by analyzing patients' tissue samples while they are still laying on the operating table under anesthesia. In addition to helping patients, this technique cuts cost by eliminating the need for follow-up surgery when analysis finds not all the cancerous tissue has been removed.
- News Cologuard Receives FDA Approval
- News CAP TODAY: “Unraveling Metastasis With Circulating Tumor Cells”
- News Mayo Clinic Researchers Discover New Form of Cancer
- News 2014 ASCO Annual Meeting
- Communiqué Molecular Diagnosis Of Bone And Soft Tissue Tumors